

Anti-Complement C5 Antibody (Eculizumab)

Introduction

Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b, thereby inhibiting the deployment of the terminal complement system, including the formation of the membrane attack complex (MAC). Eculizumab has the potential to be used in hemolytic studies.

Product parameters

Alternative Names	Soliris, h5G1.1
Target Accession	P01031
Target	Complement C5
CAS number	219685-50-4
Molecular Weight	145.74 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CO5 His at 2 ug/mL can bind Anti-Complement C5 Antibody (Eculizumab), EC50=0.9163 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

